Grifols Sa (GRFS) - News Archive

Expansion of XEMBIFY® Label in the U.S. Augments Treatment Options for Primary Humoral Immunodeficiencies Grifols, a global leader in the production of plasma-derived medicines, has recently received approval from the U...

Grifols SA, a reputable Spanish pharmaceutical company specializing in blood plasma medicines, has been making waves in the market with its impressive stock performance. Despite recent allegations and discussions surrou...

Grifols, a leading global producer of plasma-derived medicines, has announced that its subsidiary, Biotest, anticipates generating approximately $1 billion in revenue from sales of its intravenous immunoglobulin (Ig) ca...

The agreement between Grifols and Haier Group signifies a significant development in the healthcare industry, with implications for both companies future growth and expansion. The deal has successfully obtained all nece...

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.BARCELONA, Spain, April 18, 2024 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global he...

Grifols Procleix ArboPlex Assay Revolutionizes Arbovirus Screening: First 4-in-1 NAT to Receive CE MarkBARCELONA, Spain - Grifols, a global leader in plasma-derived medicines and diagnostic solutions, has recently achie...

The pioneering industrial technology company, EnWave Corporation, recently announced its collaboration with a renowned North American food company guided by a high-profile chef with multiple Michelin stars. This novel c...

Grifols, a renowned producer of plasma-derived medicines, has recently revealed positive topline results from its phase 3 clinical trial of BT524, a fibrinogen concentrate (FC) for the treatment of acquired fibrinogen d...